Article
A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia.
Brain : a journal of neurology - 3 Jun 2022
van der Ende Emma L, Bron Esther E, Poos Jackie M, Jiskoot Lize C, Panman Jessica L, Papma Janne M, Meeter Lieke H, Dopper Elise G P, Wilke Carlo, Synofzik Matthis, Heller Carolin, Swift Imogen J, Sogorb-Esteve Aitana, Bouzigues Arabella, Borroni Barbara, Sanchez-Valle Raquel, Moreno Fermin, Graff Caroline, Laforce Robert, Galimberti Daniela, Masellis Mario, Tartaglia Maria Carmela, Finger Elizabeth, Vandenberghe Rik, Rowe James B, de Mendonça Alexandre, Tagliavini Fabrizio, Santana Isabel, Ducharme Simon, Butler Christopher R, Gerhard Alexander, Levin Johannes, Danek Adrian, Otto Markus, Pijnenburg Yolande A L, Sorbi Sandro, Zetterberg Henrik, Niessen Wiro J, Rohrer Jonathan D, Klein Stefan, van Swieten John C, Venkatraghavan Vikram, Seelaar Harro
Abstract excerpt
Several CSF and blood biomarkers for genetic frontotemporal dementia have been proposed, including those reflecting neuroaxonal loss (neurofilament light chain and phosphorylated neurofilament heavy chain), synapse dysfunction [neuronal pentraxin 2 (NPTX2)], astrogliosis (glial fibrillary acidic protein) and complement activation (C1q, C3b). Determining the sequence in which biomarkers become abnormal over the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.